Intrinsiqq
Fulcrum Therapeutics Inc. logo

Fulcrum Therapeutics Inc. Insider Trading

FULC

Compare
Last 12 months

Insiders sold 434K and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Mar 2024.

Net open-market
−434K
0 buys · 4 sales
Under a 10b5-1 plan
100%
of the value sold
Insiders who bought / sold
0 / 3
executives and directors
Last open-market buy
Mar 2024
Mar 4, 2024

Get an email when FULC's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Jul 16 – 17
    Kevin Tang
    Large holder · bought 167,616 at avg $3.55
    595K
    2.4% of stake
  • Jul 13 – 15
    Tang Capital Management LLC
    Large holder · bought 249,946 at avg $3.57
    891K
    3.8% of stake
  • Jun 2610b5-1 plan
    Alan Ezekowitz
    Director · sold 18,000 at $3.65
    66K
    62% of stake
  • Feb 210b5-1 plan
    Robert J Gould
    Director · sold 15,000 at $10.72
    161K
    3.2% of stake
  • Jan 210b5-1 plan
    Robert J Gould
    Director · sold 15,000 at $10.87
    163K
    3.1% of stake
  • Dec 15, 202510b5-1 plan
    Curtis Gale Oltmans
    Chief Legal Officer · sold 3,452 at $12.92
    45K
    25% of stake
  • Dec 8, 2025No plan
    RA Capital Healthcare Fund LP
    Large holder · sold 4,175,139 at avg $13.98
    $58.4M
    41% of stake
  • Nov 19, 202510b5-1 plan
    Robert J Gould
    Director · sold 15,000 at $11.03
    165K
    3.0% of stake
  • May 8, 2025No plan
    Greg Tourangeau
    Principal Accounting Officer · sold 498 at $5.06
    3K
    3.4% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch FULC, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with FULC

CompareIntrinsic value
KURAKura Oncology Inc.
$6.91-5.99%10
GOSSGossamer Bio Inc.
$10.72-4.54%10
BCYCBicycle Therapeutics PLC
$2.90-4.92%40
LABStandard Biotools Inc.
$0.63+3.28%35
ADCTADC Therapeutics S.A.
$1.29-0.77%10
OMEROmeros Corporation
$13.21-5.71%28
AMLXAmylyx Pharmaceuticals, Inc.
$26.02-0.69%10
RMTIRockwell Medical, Inc.
$5.82-7.03%34

Held by ETFs

FULC is in 15 US ETFs. The largest of them, with FULC's weight in each:

Spot a number that looks wrong? Check it in FULC's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing FULC

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.